20-year all-cause dementia risk

1 paper1 finding

Human trial1

Interventions

1

Semaglutide

downin humans1OR 0.91

1 study

Semaglutide decreases 20-year all-cause dementia risk in humans (OR 0.91, 95% CI 0.88-0.94).
Human trialoverweight/obesity and cardiovascular disease without diabetes2.4 mg104 weeksn = 2,970
Semaglutide attenuates a proteomics-based dementia risk signature in older adults with overweight or obesity and cardiovascular disease without diabetes: A post hoc analysis of the SELECT phase 3 trial
Alzheimer's & dementia (Amsterdam, Netherlands)8 Aug 2026

More on Semaglutide

Latest

1 in 12 months

Alzheimer's & Dementia9 Aug

Semaglutide attenuates a proteomics-based dementia risk signature in older adults with overweight or obesity and cardiovascular disease without diabetes: A post hoc analysis of the SELECT phase 3 trial

Randomised trial in 2,970 peopleSemaglutide